




CORRECTION



Correction to: Infographic: Laser in Glaucoma and Ocular Hypertension Trial (LiGHT)

Nawara Behzad, Yen Ning Mau, Rashmi G. Mathew and Christin Henein 

© The Author(s), under exclusive licence to The Royal College of Ophthalmologists 2021

Eye (2022) 36:1133–1134; <https://doi.org/10.1038/s41433-021-01868-5>

Correction to: *Eye* <https://doi.org/10.1038/s41433-021-01432-1>

The original article has been corrected.

Unfortunately, an error occurred in Fig. 1. The correct Fig. 1 is given below:




Fig. 1 The Laser in Glaucoma and ocular Hypertension Trial (LiGHT) showed that at 3 years follow up initial selective laser trabeculoplasty followed by conventional medical therapy as required to reach target IOP was more cost effective than medical therapy alone for patients with ocular hypertension or primary open angle glaucoma. IOP intraocular pressure, OHT ocular hypertension, POAG primary open angle glaucoma, SLT selective laser trabeculoplasty, VA visual acuity, VF visual field. Reference to original study: Gazzard G, Konstantakopoulou E, Garway-Heath D, Garg A, Vickerstaff V, Hunter R, et al. Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicenter randomised controlled trial. *Lancet*. 2019;393(10180):1505–16.